Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study

DOI Full Paper Access

37

Citations

20

References

2019

Year

Hiroshi Kobayashi, Shintaro Iwata, Toru Wakamatsu, Keiko Hayakawa, Tsukasa Yonemoto, Junji Wasa, Hiroyuki Oka, Takafumi Ueda, Sakae Tanaka

Abstract

Initial trabectedin at 1.2 mg/m<sup>2</sup> has clinically meaningful benefits for patients with L-sarcoma and certain histological subtypes of TRS.

References

	Year	Citations

Page 1